Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Birmingham, AL
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Huntsville, AL
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Mesa, AZ
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Palm Desert, CA
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Palm Desert, CA
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Riverside, CA
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Santa Maria, CA
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Santa Maria, CA
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Upland, CA
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Jupiter, FL
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Jupiter, FL
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Vero Beach, FL
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Vero Beach, FL
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Zephyrhills, FL
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Zephyrhills, FL
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Baltimore, MD
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Saint Louis, MO
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Hickory, NC
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Middleburg Heights, OH
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Philadelphia, PA
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Orangeburg, SC
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Orangeburg, SC
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Memphis, TN
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Dallas, TX
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
Clinical Research Facility
mi
from
Mesquite, TX
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated:  3/24/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Elizabeth Vale,
An Open Label Extension Study in Participants With Rheumatoid Arthritis
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status: Enrolling
Updated: 3/24/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Elizabeth Vale,
Click here to add this to my saved trials
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Health Beliefs and Health Behavior Practices Among Minorities With Rheumatic Diseases
Status: Enrolling
Updated:  3/27/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Health Beliefs and Health Behavior Practices Among Minorities With Rheumatic Diseases
Status: Enrolling
Updated: 3/27/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
ArthroCare, Arthritis Care Research
mi
from
Gilbert, AZ
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
ArthroCare, Arthritis Care Research
mi
from
Gilbert, AZ
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
UCLA
mi
from
Los Angeles, CA
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Inland Rheumatology Clinical Trials Incorporated
mi
from
Upland, CA
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Inland Rheumatology Clinical Trials Incorporated
mi
from
Upland, CA
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Ocala Rheumatology Research Center
mi
from
Ocala, FL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Ocala Rheumatology Research Center
mi
from
Ocala, FL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
JHU Arthritis Center Baltimore
mi
from
Baltimore, MD
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
JHU Arthritis Center Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Arthritis Treatment Center
mi
from
Frederick, MD
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Arthritis Treatment Center
mi
from
Frederick, MD
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
The Mayo Clinic
mi
from
Rochester, MN
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Office of Ramesh C. Gupta, MD
mi
from
Fair Lawn, NJ
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Office of Ramesh C. Gupta, MD
mi
from
Fair Lawn, NJ
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
DJL Clinical Research
mi
from
Charlotte, NC
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
DJL Clinical Research
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Health Research of Oklahoma
mi
from
Oklahoma City, OK
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
West Tennessee Research Institute
mi
from
Jackson, TN
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
West Tennessee Research Institute
mi
from
Jackson, TN
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Accurate Clinical Research
mi
from
Houston, TX
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Accurate Clinical Research
mi
from
Houston, TX
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Pinnacle Research Group, LLC
mi
from
Anniston, AL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Pinnacle Research Group, LLC
mi
from
Anniston, AL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
TriWest Research Associates, LLC
mi
from
El Cajon, CA
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
TriWest Research Associates, LLC
mi
from
El Cajon, CA
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
The Arthritis Center
mi
from
Palm Harbor, FL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
The Arthritis Center
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
McIlwain Medical Group
mi
from
Tampa, FL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
McIlwain Medical Group
mi
from
Tampa, FL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Reliant Medical Group
mi
from
Worcester, MA
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Reliant Medical Group
mi
from
Worcester, MA
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Texas Arthritis Research Center
mi
from
San Antonio, TX
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Texas Arthritis Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Royal Prince Alfred Hospital
mi
from
Camperdown,
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Mercy Clinic Hot Springs Communities
mi
from
Hot Springs, AR
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Mercy Clinic Hot Springs Communities
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
mi
from
Long Beach, CA
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Desert Medical Advances
mi
from
Palm Desert, CA
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Physician Research Collaboration
mi
from
Lincoln, NE
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials